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Hospitalization due to heart failure (HF) exacerbation represents a major burden in health care and portends a poor long-term
prognosisforpatients.Asaresult,thereisconsiderableinteresttodevelopnoveltoolsandstrategiestobetterdetectonsetofvolume
overload, as HF hospitalizations may be reduced if appropriate interventions can be promptly delivered. One such innovation is
the use of device-based diagnostic parameters in HF patients with implantable cardioverter deﬁbrillators (ICD) and/or cardiac
resynchronization therapy (CRT) devices. These diagnostic algorithms can eﬀectively monitor and detect changes in patients’ HF
status, as well as predict one’s risk of HF hospitalization. This paper will review the role of these device diagnostics parameters in
the assessment and management of HF patients in ambulatory settings. In addition, the integration of these novel algorithms in
existing HF disease management models will be discussed.
1.Introduction
Hospitalization for heart failure (HF) is a major health bur-
denuponsociety,withanestimatedprevalenceof5.8million
and an annual incidence of 55000 in the United States alone
[1]. In the United States, exacerbation of HF resulted in
over 658000 emergence room visits annually, representing
a signiﬁcant economic cost. In addition, hospitalization due
to HF portends a poor prognosis for patients, with an
estimated in-hospital mortality of 4% [2]. A major key in
reducing HF hospitalization is the early recognition of HF
exacerbation, which in turn may lead to prompt diagnosis
and management of HF without the need for hospital
visits. Unfortunately, bedside clinical parameters are often
inaccurate in assessing the true volume status of HF patients
[3]. Moreover, symptoms leading to HF hospitalization
generally occur later in the decompensation course. For
example, dyspnea due to pulmonary congestion was only
reported within an average of 3 days prior to hospitalization
[4]. Early recognition and prompt management of HF
exacerbation has been shown to reduce hospitalization and
improvequalityoflifeforHFpatients[5,6].Asaresult,there
is considerable interest to develop strategies that facilitate
prompt recognition and management of HF exacerbations
in these patients. One such innovation is the use of device-
based diagnostic parameters to assess for signs of volume
overload and to predict the onset of HF exacerbation. These
functions are integrated within the platforms of certain
implantable cardioverter deﬁbrillator (ICD) and cardiac
resynchronization therapy (CRT) devices. They are readily
accessible from routine device interrogation and are user
friendly. The ever expanding indications of ICD and CRT
therapy will conceivably make these device-based diagnostic
parameters an indispensable tool in HF care. As such, this
paper will review the current state of knowledge regarding
the use of these device-based diagnostics in the assessment
and management of patients with systolic HF.
2.Heart RateVariability(HRV)
Heart rate variability arises from the interplay between the
two limbs of the autonomic nervous system in order to2 Cardiology Research and Practice
maintain adequate cardiac output for the body’s needs. The
parasympathetic input to the heart is primarily responsible
for HRV [7]. In humans, chronic heart failure is known to
exert deleterious alterations upon cardiac autonomic control
[8]. Derangement in the homeostatic balance of the cardiac
autonomic system is associated with poorer outcomes and
increased mortality [9, 10]. Among patients with implanted
pacing devices, continuous monitoring of HRV could be
performed by measurement of the sinus rate from the atrial
lead. In these devices, assessment of HRV was achieved by
examining the standard deviation of the 5-minute median
atrial-to-atrial depolarization interval (SDAAM). Adamson
et al. ﬁrst described the use of HRV as a device-based
diagnostic tool in HF patients [11]. In 397 patients with
systolic HF and New York Heart Association (NYHA) III
or IV symptoms with an implanted CRT, measurements of
SDAAM were correlated to their clinical course over an 18-
month period. An SDAAM < 50ms (averaged over 4 weeks)
was associated with increased all-cause and cardiovascular
mortality, with hazard ratios of 3.20 and 4.43, respectively.
In addition, SDAAM were persistently depressed during the
entire followup among patients who were hospitalized or
died. An SDAAM > 100ms was associated with a low risk
for hospitalization. Moreover, the decline in SDAAM was
found to precede HF hospitalization by a median of 16
days and returned to baseline after treatment. If changes
in the patient’s neurohormonal status precede development
of HF symptoms, continuous monitoring of SDAAM may
be a valuable tool in predicting one’s future risk of HF
hospitalization. Indeed, the interrelationship between HRV
(as reﬂected by SDAAM) and HF status has been conﬁrmed
by two studies, which showed that a favourable response
to CRT therapy was associated with increases in HRV and
concomitant decreases of the mean heart rate [11, 12]. In
current devices, measurement of SDAAM depends upon
the presence of intrinsic sinus node activity. As such, the
clinical use of SDAAM cannot be applied to patients with
persistentatrialﬁbrillation(AF)orifatrialpacingisrequired
>80% over a 24-hour period, since SDAAM cannot be
accurately measured in these situations [11]. Taken together,
however, measurement of HRV by SDAAM appears to be a
valid clinical tool in assessing one’s HF status and risk of
subsequent HF hospitalization.
3. IntrathoracicImpedance
Assessment of thoracic ﬂuid status by measuring intratho-
racic impedance is the newest device-based diagnostic tool
availableinclinicalpractice.Thisisbasedontheconceptthat
changes of ﬂuid volume in the lungs will alter intrathoracic
impedance [13, 14]. The OptiVol ﬂuid status monitoring
algorithm (Medtronic, Inc., Minneapolis, USA) is incor-
p o r a t e di nc o n t e m p o r a r yI C Da n dC R T - Dp l a t f o r m s .I n
these systems, intrathoracic impedance is measured between
the pulse generator (usually implanted in the left pectoral
region) and the right ventricular coil of the ICD lead. This
vector encompasses most of the left thoracic cavity and
deﬁnes the intrathoracic impedance as measured by the
device. Using the concept of Ohm’s law, impedance of the
hemithorax cavity is measured upon delivery of a small
alternating current between the pulse generator and the
ICD lead. Since ﬂuid (water, blood) is a highly conductive
medium, accumulation of ﬂuid in the lungs will lower
intrathoracic impedance. A purported advantage of this
algorithm is the reproducibility and consistency of repeated
measurementsduetotheﬁxedpositionsofthetwoelectrodes
[15]. This makes data trending possible and allows clinicians
to follow the pulmonary ﬂuid status of patients over time.
The OptiVol ﬂuid status monitor is activated ≥34 days
after the index procedure in order to prevent spurious mea-
surements due to air and edema in the healing pocket. Once
active, the device will measure the intrathoracic impedance
every 20 minutes between noon and 5pm, totalling 64
recordings. These values are averaged and reported as the
“daily impedance value”. Daily measurements of impedance
are compared to the patient’s reference value, which is
derived from the average of the last 4 daily impedance
recordings. Negative deviations of the daily impedance value
generate the OptiVol ﬂuid index (Figure 1). The OptiVol
index has a unit measurement of ohms·days and is com-
pared to a programmable ﬂuid index which is nominally
set as 60ohms·days. The OptiVol ﬂuid index is plotted
against time to provide two pieces of information: (i) the
magnitude of the deviation from the programmable ﬂuid
index threshold; (ii) the time duration of the deviation.
Pulmonary ﬂuid retention will generate negative deviations
of the daily impedance from the reference value, which is
graphically depicted as deviations from the zero baseline
value in the OptiVol index.
The OptiVol index only provides an indirect mea-
surement of pulmonary congestion based on intrathoracic
impedancechanges.Assuch,false-positiveandfalse-negative
measurements can occur and need to be borne in mind
when this tool is applied in clinical practice. For example,
air trapping in emphysematous lungs may mask decreases
in intrathoracic impedance. On the other hand, alveolar
congestion from pneumonia or the presence of pleural
eﬀusions will lower daily impedance measurements even
though pulmonary congestion due to elevation of left-sided
cardiac pressures had not occurred. Furthermore, not all
patients experience pulmonary congestion as their dominant
HFexacerbationsymptom.Thus,theOptiVolalgorithmmay
not be useful in assessing patients with predominant right-
sided heart failure symptoms, or those with low cardiac
output despite being relatively euvolemic. In spite of these
potential limitations, considerable interests exist in utilizing
the OptiVol ﬂuid index to prevent, assess, and manage heart
exacerbation events due to pulmonary congestion in patients
with implantable cardiac devices.
4.ClinicalData
The ﬁrst proof-of-concept study of OptiVol use in humans
was reported by Yu et al. in the Medtronic Impedance
Diagnostics in Heart Failure Patients Trial (Mid-HeFT)
[16]. A special pacemaker with an ICD lead was implanted
in 33 patients with systolic HF and NYHA class III or IV
symptoms. Daily intrathoracic impedance was recordedCardiology Research and Practice 3
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Figure 1: OptiVol ﬂuid index. The intrathoracic impedance is
measured on a daily basis and is compared to the patient’s
“reference” value, which is derived from the average of the last
4 daily measurements. Negative deviations from the reference
value suggest a decrease in intrathoracic impedance, which may
reﬂectpulmonarycongestion.Thediﬀerencebetweenthemeasured
intrathoracic impedance and the reference value is multiplied by
time (measured in days) to generate the OptiVol ﬂuid index, which
has a unit measurement of ohms·days. The magnitude of the ﬂuid
index value is determined by (i) the absolute diﬀerence between
the reference value and the measured intrathoracic impedance,
and/or (ii) the time duration of the diﬀerence. The ﬂuid index is
plotted against time to graphically display the onset and duration of
negative deviations of intrathoracic impedance. The nominal cut-
oﬀ threshold is set as 60 ohms·days.
by the device, and physicians were blinded to these
measurements. In the acute phase of the study, patients with
decompensated HF were hospitalized in the coronary care
unit and treated with intravenous diuretics and vasodilators.
The pulmonary capillary wedge pressures (PCWP) of these
patients were measured by pulmonary artery catheters
every 2 hours. Intrathoracic impedance was measured
by the device every 6 hours in this patient subgroup. A
total of 9 patients experienced 24 hospitalizations for HF
exacerbation, and PCWP measurements were recorded in 5
patients with 14 hospitalizations. A statistically signiﬁcant
inverse relationship was noted between the PCWP and
intrathoracic impedance. As patients were being diuresed, a
concomitant increase in intrathoracic impedance was noted.
In addition, a statistically signiﬁcant inverse correlation was
demonstrated between net ﬂuid loss during hospitalization
and intrathoracic impedance. Furthermore, a decrease in
intrathoracic impedance preceded the onset of dyspnea
by 15.3 ± 10.3 days (mean ± standard deviation), which
was considerably earlier than the actual onset of symptoms
which led to hospitalization (3.0 ± 2.5 days). The drop in
intrathoracic impedance which occurred before onset of HF
symptoms and at HF admission were signiﬁcantly reduced
(P<. 001). Thus, the authors conclude that OptiVol may
help detect early onset of volume overload, which in turn
may predict onset of HF exacerbation.
In the chronic phase of the study, patients were followed
by an ambulatory heart function clinic on a regular basis
and were managed by physicians who had no knowledge
of the intrathoracic impedance measurements. If a patient
was hospitalized for HF exacerbation, the intrathoracic
impedance values of the preceding 30 days were used
to generate the diagnostic parameters of OptiVol. The
algorithm development data was derived from 7 patients
(11 hospitalizations from 4 patients) and was validated
in a cohort of 23 patients (13 hospitalizations from 8
patients). A receiver-operator curve (“performance curve”)
was constructed to assess the diagnostic sensitivity and
speciﬁcity of varying thresholds for impedance changes
whichmaypredictHFhospitalization.Basedontheseresults,
ac u t o ﬀ value below 60Ω·days was able to detect impedance
changes preceding HF hospitalization with a sensitivity of
76.9%. Although the speciﬁcity of this cut-oﬀ value in
predicting HF hospitalization was not explicitly stated in
the study, the authors reported a false-positive rate of 1.5
detections per patient-monitoring year. On the basis of
this study, the nominal cut-oﬀ threshold for pulmonary
congestion detection is set as 60Ω · days in the OptiVol
algorithm.
The diagnostic performance of the OptiVol algorithm
in a “real-world” population was reported by Vollmann et
al. from an observational registry of 373 patients implanted
with the Medtronic InSync Sentry CRT-D device [18]. In
this study, an audible alert was programmed when the
intrathoracic impedance fell below the cut-oﬀ threshold.
Patient followup included regular clinic appointments and
unscheduled visits due to alert activation or clinical HF
deterioration. A clinical HF exacerbation diagnosed within
2 weeks of the initial alert was classiﬁed as a “true-
positive alert event”. The treating physicians had knowledge
of the OptiVol measurements. A total of 53 alert events
occurred in 45 patients, and 53 clinical HF exacerbation
events occurred in 43 patients. OptiVol was able to detect
clinical HF exacerbation with an adjusted sensitivity of
60% and a positive predictive value of 60%. The false-
positive detection rate was 0.2 event per patient year. In
more than half of the clinical HF events (55%) which
did not trigger an alert, the intrathoracic impedance had
decreased below the reference value but had not crossed the
programmed cut-oﬀ threshold. Thus, the authors suggested
that the diagnostic sensitivity of OptiVol might be improved
if the cut-oﬀ threshold values could be individualized.4 Cardiology Research and Practice
Table 1: Device diagnostics parameters and algorithms from the Cardiac Compass report.
Device
diagnostic
parameter
Description Algorithm
AF duration Total amount of time spent during AF on a daily basis. AF ≥ 6hon≥1 day in patients without persistent AF (7
consecutive days with ≥23h AF).
Ventricular rate
during AF The daily average ventricular rate during AF. AF = 24h and the average ventricular rate ≥90
beats/min during AF on ≥1d a y .
Fluid index
(OptiVol)
The ﬂuid index trend is the cumulative diﬀerence
between the daily average and patient-speciﬁc reference
intrathoracic impedance.
High ﬂuid index on ≥1 day; thresholds included ≥60;
≥80; ≥100Ω ·days.
Patient activity
Measures the total active time per day using a capacitive
accelerometer. A minute is considered active if the
count exceeds a threshold equivalent to walking 70
steps/min.
Average patient activity <1hover1week.
Night heart rate Measures the ventricular rate from midnight to 4AM. Average night heart rate > 85 beats/min for 7
consecutive days.
Heart rate
variability
(HRV)
HRV is assessed by the SDAAM (standard deviation of
the 5-minute median atrial rate). HRV is not measured
if atrial pacing occurs >80% of the time or if the patient
is in AT/AF.
HRV < 60ms everyday for 1 week (minimum 5
consecutive days).
Percentage of
CRT pacing Percentage of biventricular pacing on each day. Biventricular pacing <90% for 5 of 7 days.
ICD shocks for
VT or VF
Records if an ICD shock was delivered for episodes
detected within the VT or VF zone; includes both
appropriate and inappropriate shock(s).
≥1 shock(s) during the evaluation period.
Adapted from [17].
AF =atrialﬁbrillation;AT/AF =atrialtachycardia/atrialﬁbrillation;CRT =cardiacresynchronizationtherapy;HF =heartfailure;HRV =heartratevariability;
ICD = implantable cardioverter deﬁbrillator; VF = ventricular ﬁbrillation; VT = ventricular tachycardia.
Programmable ﬂuid index thresholds are available in
Medtronic ICD and CRT-D platforms.
Although the use of individual HF device diagnostic
parameters has been validated in multiple clinical studies,
each parameter has potential limitations which may restrict
its general applicability in a complex HF population. As a
result, there is considerable interest in combining HF device
diagnostic parameters in the management of HF patients
with implanted devices. The PARTNERS HF (Program to
Access and Review Trending Information and Evaluate Cor-
relation to Symptoms in Patients with Heart Failure) study
was a multicenter, prospective observational study which
evaluated the use of combined HF diagnostic information in
predicting clinical deterioration of ambulatory HF patients
[17]. A cohort of 694 patients with systolic HF and NYHA
III or IV symptoms with Medtronic CRT-D devices were
prospectively evaluated in 100 centers in the United States.
Individual HF diagnostic parameters were collected from
the Cardiac Compass report (Figure 2), which consisted
of (i) atrial ﬁbrillation (AF) duration; (ii) ventricular rate
during AF; (iii) ﬂuid index (OptiVol); (iv) patient activity;
(v) night heart rate; (vi) heart rate variability; (vii) per-
centage of CRT pacing; (viii) ICD shocks for ventricular
arrhythmias (Figure 1). The deﬁnition of a “positive” event
for each parameter was prespeciﬁed (Table 1). Occurrence
of HF events were prospectively collected and independently
adjudicated. A combined HF device diagnostic algorithm
was developed by the authors and was triggered when (i)
the ﬂuid index exceeds 100Ω · days or (ii) any 2 of the 8
prespeciﬁed parameters were positive. In total, 90 patients
had 141 adjudicated HF hospitalizations with pulmonary
congestion. The combined HF device diagnostic algorithm
was triggered in 43% (298 of 694) of patients and in 23%
(1324 of 5693) of device evaluations. Having ≥2 of the 8
criteria being positive accounted for the majority (72%) of
the algorithm triggers. Importantly, patients with a positive
combined HF device diagnostic were at greater risk of
HF hospitalization with pulmonary congestion in the next
month than those without (adjusted hazard ratio: 4.8, 95%
conﬁdence interval: 2.9 to 8.1, P<. 0001). Among patients
with a negative combined HF device diagnostic, the risk of
HF hospitalization due to pulmonary congestion was 0.7%
over the next 30 days. In subgroup analyses, the predictive
ability of the combined HF device diagnostic algorithm was
greater when device evaluations were performed monthly
and semimonthly when compared to every 3 months.
However, the diagnostic utility of this algorithm appeared
to be limited to patients without prior HF events. These
observational studies highlight the promising role ofOptiVol
and other device-based diagnostics in the early detection
of pulmonary congestion in HF patients. Whether the use
of such device diagnostics can improve outcomes in HF
patients with ICD or CRT-D is currently examined by two
randomized trials, the Diagnostic Trial in Heart Failure
(DOT-HF) in Europe and the Prospective, Randomized
Evaluation of Cardiac Compass with OptiVol in the EarlyCardiology Research and Practice 5
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Figure 2: Cardiac Compass report. The Cardiac Compass report displays a number of device diagnostic parameters over a period of weeks
to months. This allows trending of data over time, allowing clinicians to monitor the heart failure status of patients. An abnormal reading
(such as a ﬂuid index threshold crossing) may reﬂect a worsening of the patient’s heart failure (HF) status, potentially alerting the physician
to a possible HF exacerbation in the near future. The combined use of multiple device parameters may improve the diagnostic sensitivity of
early HF detection.6 Cardiology Research and Practice
Detection of Decompensation Events for Heart Failure
(PRECEDE-HF) trial in North America.
5. Integrationof Device Diagnosticsinto
HeartFailureClinics
The feasibility of routine OptiVol assessment in an HF
disease management program was recently reported by
Mullens et al. [19]. In this pilot study, changes in the ﬂuid
index were assessed in 194 HF patients with an implanted
ICD or CRT-D via an online remote monitoring system
(Carelink, Medtronic, Inc.). Regular Carelink uploads were
reviewed by an HF clinic nurse. If the ﬂuid index crossed the
nominal threshold (60Ω · days) for ≥10 days, a followup
telephone call was performed by a nurse. Over a period
of 4 months, 400 Carelink uploads were received and 44
ﬂuid index threshold crossings were noted in 34 patients.
Thirty-two of the 34 (97%) patients reported occurrence
of “clinically relevant events” at around the time of ﬂuid
index threshold crossing, which included HF hospitalization
(18%); changes in HF therapy (56%); drug and/or dietary
nonadherence (38%). The incidence of clinically relevant
events was not reported in the remaining 160 patients
who did not cross the ﬂuid index threshold. In this study,
an internet-based program to detect ﬂuid index threshold
crossing yielded a high rate of clinically relevant events in
a “real-world” population of ambulatory HF patients with
implanted pacing devices. The authors concluded that use
of OptiVol in an established HF program is feasible and
willprovideadditional usefulclinicalinformationtomedical
providers.
6. Conclusions
The expanding implant indications for ICD and CRT will
result in increasing numbers of HF patients receiving these
life-saving therapies. Clinical studies had demonstrated the
utility of certain device-based diagnostic parameters in
assessing pulmonary congestion and in predicting one’s risk
of future HF hospitalization. In particular, intrathoracic
impedance assessment by OptiVol is a promising tool in
detecting early signs of pulmonary congestion, which in turn
may reduce hospitalization with prompt recognition and
treatment. The combined use of various device diagnostics
has recently been shown to be a powerful predictor of short-
term HF hospitalization risk. Ongoing randomized trials
are being performed to evaluate whether these algorithms
can improve patient outcomes. If these algorithms can
indeed improve HF outcomes, how best to integrate them
into existing HF disease management models will certainly
become an active area of research.
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